Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652131 | 0.86 | KCNH2 (0.52) | SIGMAR1KCNH2 | |
| SCHEMBL19658476 | 0.86 | CHRM2 (0.57) | CHRM2CHRM3MCHR1SIGMAR1CCR5 | |
| SCHEMBL13588400 | 0.85 | SIGMAR1 (0.62) | CHRM2CHRM3SIGMAR1ACHEKCNH2 | |
| SCHEMBL19652125 | 0.82 | CCR5 (0.51) | SIGMAR1CCR5ACHEKCNH2MEN1 | |
| SCHEMBL10893210 | 0.81 | CHRM2 (0.56) | CHRM2CHRM3SIGMAR1ACHEMEN1 | |
| SCHEMBL5862792 | 0.80 | KCNH2 (0.72) | CHRM2CHRM3MCHR1SIGMAR1CCR5 | |
| SCHEMBL19652090 | 0.78 | SIGMAR1 (0.54) | CHRM2CHRM3SIGMAR1CCR5ACHE | |
| SCHEMBL6990156 | 0.75 | S1PR5 (0.67) | SIGMAR1MEN1KMT2A | |
| SCHEMBL3599854 | 0.75 | CCR5 (0.58) | CHRM2CCR5ACHEKCNH2 | |
| SCHEMBL2390775 | 0.74 | MEN1 (0.68) | CHRM2CHRM3MCHR1SIGMAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | CHRM2 1058/4885CHRM3 1613/4885MCHR1 2667/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CHRM2 1058/4885CHRM3 1613/4885MCHR1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.